X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4848) 4848
Book Review (1029) 1029
Publication (448) 448
Conference Proceeding (55) 55
Book Chapter (20) 20
Magazine Article (4) 4
Dissertation (3) 3
Data Set (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
progression-free survival (3946) 3946
index medicus (3602) 3602
humans (3439) 3439
oncology (2670) 2670
female (2208) 2208
middle aged (1911) 1911
male (1871) 1871
aged (1674) 1674
adult (1401) 1401
cancer (1348) 1348
chemotherapy (1335) 1335
prognosis (1160) 1160
treatment outcome (1134) 1134
disease-free survival (1083) 1083
survival (1020) 1020
overall survival (834) 834
antineoplastic combined chemotherapy protocols - therapeutic use (790) 790
care and treatment (785) 785
retrospective studies (753) 753
hematology (700) 700
aged, 80 and over (688) 688
metastasis (641) 641
antineoplastic agents - therapeutic use (581) 581
analysis (553) 553
therapy (535) 535
patients (495) 495
research (494) 494
tumors (488) 488
neoplasm staging (477) 477
kaplan-meier estimate (447) 447
survival analysis (447) 447
clinical trials (444) 444
disease progression (442) 442
surgery (423) 423
survival rate (419) 419
medicine & public health (408) 408
development and progression (392) 392
progression-free (389) 389
patient outcomes (381) 381
young adult (380) 380
hematology, oncology and palliative medicine (368) 368
medical prognosis (345) 345
rituximab (338) 338
time factors (333) 333
carcinoma (329) 329
radiotherapy (329) 329
risk factors (313) 313
drug therapy (304) 304
follow-up studies (304) 304
adolescent (298) 298
progression free survival (296) 296
bevacizumab (293) 293
trial (293) 293
breast cancer (288) 288
phase-ii trial (281) 281
non-hodgkins-lymphoma (278) 278
health aspects (277) 277
neoplasm metastasis (274) 274
cancer therapies (272) 272
proportional hazards models (270) 270
abridged index medicus (268) 268
transplantation (268) 268
open-label (266) 266
pharmacology & pharmacy (266) 266
phase-iii trial (264) 264
recurrence (260) 260
combined modality therapy (259) 259
clinical neurology (254) 254
biomarkers (246) 246
antineoplastic combined chemotherapy protocols - adverse effects (244) 244
medical research (241) 241
ovarian cancer (241) 241
phase-iii (239) 239
randomized controlled trials as topic (238) 238
diagnosis (232) 232
mutation (232) 232
phase-ii (231) 231
metastases (230) 230
expression (228) 228
multivariate analysis (219) 219
immunotherapy (217) 217
colorectal cancer (210) 210
lymphomas (207) 207
cisplatin (202) 202
article (201) 201
studies (197) 197
lung cancer (196) 196
glioblastoma (195) 195
prospective studies (195) 195
radiology, nuclear medicine & medical imaging (195) 195
randomized-trial (195) 195
toxicity (193) 193
antineoplastic agents - administration & dosage (190) 190
efficacy (190) 190
usage (189) 189
lung neoplasms - drug therapy (186) 186
antineoplastic agents (179) 179
radiation-therapy (178) 178
clinical trials as topic (177) 177
clinical-trials (176) 176
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4702) 4702
Chinese (55) 55
German (39) 39
French (27) 27
Spanish (26) 26
Korean (18) 18
Russian (14) 14
Polish (9) 9
Czech (5) 5
Hungarian (5) 5
Japanese (4) 4
Turkish (3) 3
Portuguese (2) 2
Dutch (1) 1
Esperanto (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Statistics in Medicine, ISSN 0277-6715, 02/2019, Volume 38, Issue 5, pp. 703 - 719
This paper considers methods for estimating the association between progression‐free and overall survival in oncology trials. Copula‐based, nonparametric, and... 
overall survival | Kendall's | copula | progression‐free survival | inverse probability of censoring weights | multistate model | Kendall's τ | progression-free survival | Oncology
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 04/2018, Volume 40, Issue 4, pp. 628 - 639.e3
Purpose: The comparative efficacy of endocrine-based therapies (ETs) for hormone receptor–positive/human epidermal growth factor receptor 2–negative... 
targeted therapy | network meta-analysis | progression-free survival | metastatic breast cancer | endocrine therapy | HR positive/HER2 negative | COMBINATION | CHEMOTHERAPY | ANASTROZOLE | network meta analysis | EVEROLIMUS PLUS EXEMESTANE | PALBOCICLIB | ISPOR TASK-FORCE | FULVESTRANT | LETROZOLE | PHARMACOLOGY & PHARMACY | AMERICAN-SOCIETY | Aromatase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Proportional Hazards Models | Receptor, ErbB-2 - metabolism | Breast Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Disease-Free Survival | Progression-Free Survival | Bayes Theorem | Postmenopause | Female | Network Meta-Analysis | Development and progression | Breast cancer | Postmenopausal women | Epidermal growth factor | Metastasis | Analysis | Identification methods | Medical services | Clinical trials | Oncology | Cancer therapies | Subgroups | Fulvestrant | Metastases | Literature reviews | Randomization | Upper bounds | Aromatase | Significance | Medical research | Effectiveness | Statistical analysis | Anastrozole | Mortality | Endocrine therapy | Hazards | Patients | Survival | ErbB-2 protein | Quality of life | Post-menopause | Studies | Chemotherapy | Womens health | Medical prognosis | Death | Society | Bayesian analysis | Cancer | Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2018, Volume 19, Issue 10, pp. 1315 - 1327
Journal Article
International Journal of Cancer, ISSN 0020-7136, 06/2018, Volume 142, Issue 12, pp. 2589 - 2598
Journal Article